At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 103 enrolled
Drug / intervention
PF-06473871 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
In Brief
A Phase 2 clinical trial evaluating PF-06473871 for Reduction of Hypertrophic Skin Scarring. Completed, enrolled 103 participants across 40 sites in 4 countries.
Detailed Summary
The study will compare how well PF-06473871 works versus placebo in reducing skin scarring after scar revision surgery of existing breast scars. The study will also evaluate the safety of PF-06473871 in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReduction of Hypertrophic Skin Scarring
CountriesGermany, Hungary, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedNov 21, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.6 years ago
Interventions
PF-06473871drug
Single dose administered by injection four different times
PF-06473871drug
Single dose administered by injection three different times